yemenjmedYemen Journal of MedicinecoVolume 4 Issue 1MultidisciplinaryEnglishJanuary- April 2025NNY20250525ArticleRegional Disparities in Covid-19 Vaccine Distribution: A Global Analysis of Manufacturer Contributions and Product AvailabilityEnglishY193197Mostafa EssamEissa1EnglishN10.63475/yjm.v4i1.0095NO ABSTRACTEnglishhttps://yemenjmed.com/admin/abstract?id=165References1619University of Glasgow. Study reveals major gaps in global COVID-19 vaccine access. Univ Glasgow. 2025 Mar 18 [cited 2025 Apr 28]. Available from: https://www.gla.ac.uk/explore/glasgowsocialscienceshub/resources/all/headline_1163770_en.htmlAbu El Kheir-Mataria W, Khadr Z, El Fawal H, Chun S. COVID-19 vaccine intercountry distribution inequality and its underlying factors: a combined concentration index analysis and multiple linear regression analysis. Frontiers in Public Health. 2024 Mar 21;12:1348088.RVMC. The time for regionalised vaccine manufacturing has arrived. RVMC. 2025 Jan 13 [cited 2025 Apr 29]. Available from: https://rvmc.net/time-regionalised-vaccine-manufacturing-has-arrived-0Africa CDC. Africaand;#39;s progress towards sustainable local manufacturing health products. Africa CDC. 2025 Feb 11 [cited 2025 Apr 30]. Available from: https://africacdc.org/news-item/africas-progress-towards-sustainable-local-manufacturing-health-products/Herder M, Benavides X. and;#39;Our project, your problem?and;#39; A case study of the WHOand;#39;s mRNA technology transfer programme in South Africa. PLOS Glob Public Health. 2024 Sep 23;4(9):e0003173.An D, Lim M, Lee S. Challenges for data quality in the clinical data life cycle: systematic review. J Med Internet Res. 2025 Apr 23;27:e60709.Kim J, Lee TJ, Hwang SS. Verifying the quality and consistency of immunization monitoring systems. Bull World Health Organ. 2008 Dec;86(12):953-60.Inward RP, Jackson F, Dasgupta A, Lee G, Battle AL, Parag KV, et al. Impact of spatiotemporal heterogeneity in COVID-19 disease surveillance on epidemiological parameters and case growth rates. Epidemics. 2022 Dec 1;41:100627.Wang X, Pahwa A, Bausch-Jurken MT, Chitkara A, Sharma P, Malmenand;auml;s M, et al. Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among adults with underlying medical conditions: systematic literature review and pairwise meta-analysis using GRADE. Adv Ther. 2025 Mar 10:1-38.Kopel H, Nguyen VH, Bogdanov A, Winer I, Boileau C, Ducruet T, et al. Comparative effectiveness of the bivalent (Original/Omicron BA. 4/BA. 5) mRNA COVID-19 vaccines mRNA-1273.222 and BNT162b2 bivalent in adults with underlying medical conditions in the United States. Vaccines. 2024 Sep 27;12(10):1107.Hay M, Teichert A, Kilz S, Vosen A. Resilience in the vaccine supply chain: learning from the COVID-19 pandemic. Vaccines. 2025 Jan 29;13(2):142.Medicines Patent Pool. Global mRNA technology transfer programme. MPP. [cited 2025 Apr 27]. Available from: https://medicinespatentpool.org/what-we-do/mrna-technology-transfer-programmeBottini Filho L, Abdool Karim S, Fish Hodgson T. Vaccine Inequity in the COVID-19 Crisis: lessons to leverage global health law through market-shaping policies. J Law Med Ethics. 2025 Mar 27;48(S1):17-27.Khor SS. New trends in SARS-CoV-2 variants and vaccines. Vaccines. 2025 Mar 3;13(3):265.Pavia G, Branda F, Ciccozzi A, Romano C, Locci C, Azzena I, et al. Integrating digital health solutions with immunization strategies: improving immunization coverage and monitoring in the post-COVID-19 era. Vaccines. 2024 Jul 28;12(8):847.